Audits/Inspections Be Prepared for Anything
|
|
- Sheena Greer
- 6 years ago
- Views:
Transcription
1 Audits/Inspections Be Prepared for Anything Practices, laboratories, institutions, and clinics that participate in clinical trials are subject to audits by a number of different entities. As a primary investigator, it is important for you to be prepared for these, sometimes unannounced, visits because the outcomes can have a significant impact on your site and the overall clinical study. This chapter will contain information on what entities may make a visit to your site, what the auditor or inspector will be looking for, and how to conduct yourself during the actual inspection. The authority to audit/inspect is under the jurisdiction of a number of agencies, organizations, and institutions. In the United States, oversight falls under the US Food and Drug Administration (FDA), whereas Canada relies on the Health Products and Food Branch Inspectorate (HPFBI); the European Medicines Agency (EMEA) Inspections Services Group is in Europe, and the Ministry of Health, Labor, and Welfare is in Japan. Other possible inspections may come from trial sponsors or the supervising institutional review board (IRB) or research ethics committee (REC). Sponsors The first audit of your clinic by the sponsor will occur before any contracts are signed to determine if your facilities are appropriate to meet the needs of the study; for example, if bone mineral density scans will be required, does your clinic have a dual energy x-ray absorptiometry (DEXA) machine? Once the study has started, it is the sponsor s responsibility to periodically monitor its investigators. Thus, the sponsor s monitors may visit your site frequently to ensure that you are following the protocol and all applicable regulations. During these periodic visits, the monitor will look at all of your records. They will review the data for accuracy and completeness. If the study is blinded, these monitors will remain blinded. In 1988, the FDA set out guidelines for sponsors regarding the monitoring of clinical investigations, and they have been more recently updated. Although these guidelines are not legal requirements, they establish a model standard of practice the FDA wants sponsors and monitors to follow. Institutional Review Boards Your IRB/REC may also conduct an audit of your clinic. They are similar to the ones conducted by the FDA. Meetings will be scheduled before the visit to examine your study-related records that they have on file. They will be checking to make sure you are following all policies and procedures of the institution, which may be more stringent than that of either the sponsor or the FDA. Governmental Authority The United States The FDA s Bioresearch Monitoring program (BIMO) oversees inspections both nationally and internationally if the data is critical to product approval in the United States. They inspect approximately 1% of all clinical trial sites each year. At their discretion, 2 types of inspections may occur at any facility at any time: routine and directed. Routine inspections are performed when a site is randomly selected with no specific reason to audit. Directed inspections, or for cause inspections, occur when a specific problem, such as a safety concern, complaint, or clinical investigator misconduct, is identified by the FDA. The purpose of an FDA routine inspection is to verify:
2 Who performed various aspects of the protocol (eg, who verified inclusion and exclusion criteria, who obtained informed consent, who collected adverse event data); The degree of delegation of authority (eg, how the clinical investigator supervised the conduct of the investigation); Where specific aspects of the investigation were performed; How and where data were recorded; Accountability for the investigational product; The monitor s communications with the clinical investigator; and The monitor s evaluations of the progress of the investigation. The FDA requires that all files be kept for a minimum of 2 years after the trial has been published or discontinued by the sponsor, unless specified otherwise. The FDA has the authority to view, copy, and verify any records or reports made by the clinical investigator regarding the disposition of the product and subject case histories. The FDA inspector may also audit the study data, comparing what is on file with the FDA or study sponsor with what is contained in the individual investigator s files. However, they will not attempt to interpret or evaluate the data. Material they may review includes the informed consent forms, correspondence between you and the sponsor and the IRB, and medical records (eg, physician notes, hospital charts), not only from the trial but also files that predate the study to determine that eligibility criteria were met and post-study files to determine if proper follow-up was performed. The FDA s access to medical records should be included in the confidentiality agreement with the subjects. The FDA inspection is limited to the conduct of the clinical trial. They will not be reviewing your regular clinic business or your skill as a physician. At the conclusion of the audit, the FDA inspector will conduct an exit interview with the clinical investigator to discuss the findings. A written Establishment Inspection Report (EIR) will also be submitted to the FDA. After review of the EIR, 1 of the 3 of the following types of letters will be sent out to the investigator. A letter stating nothing deviated from the regulations. Sometimes this type of letter is not sent. An informational or untitled letter that identifies deficiencies in meeting statues and regulations and for which voluntary corrective action is needed. A warning letter that identifies serious deviations from statutes and regulations. Prompt correction of the deficiencies and a written response to the FDA is required. The FDA also has the authority to disqualify clinical investigators from participating in future clinical trials if the investigator repeatedly or deliberately fails to comply with applicable statutory or regulatory requirements or has submitted false information to the sponsor or the FDA.
3 Canada Canadian regulation falls under the jurisdiction of the HPFBI. Their Compliance and Enforcement Policy provides the guiding principles for the fair, consistent and uniform application and enforcement of the Act and Regulations (Health Product and Food Branch Inspectorate 2008). The European Union European oversight falls to the Good Clinical Practice Inspection Services Group of the EMEA. Their inspectors use the Joint Audit Programme to ensure conformity among nations throughout the inspection process, and to make sure trials stay in accordance with mutual recognition agreements among European countries. In Great Britain specifically, the Medicines and Healthcare products Regulatory Agency works in conjunction with the EMEA to safeguard public health. Japan In Japan, the Ministry of Health, Labor, and Welfare is the authority on medical research. The Pharmaceutical Affairs Law was enacted with the basic goal of regulating the efficacy, quality, and safety of pharmaceuticals, medical devices, and cosmetics. This law promotes harmony with similar mandates of the United States, European Union, and other countries. Preparing for an Audit Preparing for an inspection should be started as soon as you agree to be involved in a study and should continue even after the study is completed. One of the easiest and most important things you can do is keep all of your paperwork regarding the conduct of the study, including protocols, patientspecific information, and reports well organized and easy to access. All of your staff involved in the study should be familiar with the protocol and applicable institution, sponsor, and governmental regulations, and one person should be assigned to assist the inspector throughout the day. It is also important that you alert the study sponsor of any government visits or audit requests, so they can be prepared to provide additional information as needed. Strategies for Success During a Regulatory Agency Inspection Although the prospect of a regulatory agency inspection is daunting, you can help it go smoothly by following these tips. Remember that first impressions are important, so be available and assume a cooperative attitude. When the inspection agent arrives, regardless of whether he or she represents the government, the sponsor, or the IRB, the first thing to do is ask for credentials to ensure that confidential files are not being seen by unauthorized persons. Once you have verified that the person is truly an authorized inspector, give him or her access to any study-related materials requested. When asked a question, confirm that you understand what is being asked before answering, and be brief and factual with your responses. Take immediate corrective action, if possible, and correct any misinformation, as appropriate. Make sure you are also readily available to the inspector at any time in case he or she needs clarification or is unable to locate important documents. Following the inspection, you may receive a written report of the findings. Respond promptly and factually to whatever requests are made. Do not volunteer any information without being asked; do not guess or offer opinions, be argumentative, delay responses to requests, entertain hypothetical questions, or answer questions outside your expertise. For additional suggestions, please see Table 1.
4 If you are well organized, pay attention to detail, and run the trial ethically, you should be able to avoid the common deficiencies listed below. Common Inspection Findings Informed consent inadequacies Example, old draft used to obtain consent Protocol nonadherence Example, drug stored at the wrong temperature Inadequate/inaccurate records Example, wrong units used for evaluation parameter Records not available Example, missing hard-copy informed consent forms Inadequate investigational article accountability Example, missing investigational compound for 2 patients for final dosing Inaccurate case histories Example, missing initial blood pressure data Unapproved concomitant therapy Example, subject took aspirin for a temporary headache when prohibited by protocol IRB not informed of protocol changes Example, sponsor changes the machine used in bone density evaluation Subinvestigators not listed Example, colleague doing initial subject evaluations not reported to IRB Failure to report serious adverse events (SAEs) Example, heart attack not recorded because subject dropped out of the trial Inappropriate follow-up of AEs Example, subject sent to hospital, with subsequent transfer of care Subjects enrolled into simultaneous investigations Example, subject in a trial of topical acne medication and another for a blood pressure drug Submission of false information Example, data transferred from one date to another date Inappropriate delegation of duties Example, clinical trial coordinator is evaluating lesions Conclusions Although they are intimidating, audits should not be looked at as a negative but rather a positive opportunity to improve your clinical trial methods. Becoming familiar with those regulations related to clinical trials will not only help you be prepared for an audit, but will also allow you to better run your clinic. The key to getting through an audit is organization and preparation, things that are applicable to all aspects of your practice. Table 1: Strategies for Success During a Regulatory Agency Inspection Contact from the Regulatory Agency Planning for the Regulatory Agency Visit Ensure that Obtain the inspector s name, office location and telephone number. Confirm the studies to be evaluated. Verify the intended dates for the inspection. Ask is sponsor personnel can be present during the inspections. Provide the sponsor with the above information. All study staff, including the pharmacy and support laboratories, are informed of the dates of the Regulatory Agency visit and the studies to be review. A room free of other sponsors study information is booked for the inspector to work in.
5 Someone is assigned to assist the inspector this may be all day if the inspector is not familiar with the clinical studies or the therapeutic area. Arrangements are made for all study staff to meet the inspector on the first day, at the opening meeting. All versions of the original signed informed consent forms are available All medical records pertaining to eligibility and the study period are available. If your site uses electronic medical records, review your local institutions policies on access methods for inspectors. All case report forms and queries are available and legible. If your site uses and electronic data capture (EDC) system in place of paper case report forms, contact the sponsor for guidance on how to make this information available to the inspectors. The regulatory binder is available and complete. The subjects results for central laboratory analyses are available. Preparing for the Regulatory Agency Visit Refresh your memory about During the Inspection Do s During the Inspection Don ts Meetings and training sessions about the protocol and amendments. Each subject s progress through the study- pay special attention to serious adverse events. Protocol deviations and what procedural changes were implemented to prevent future occurrences. Drug management issues. Inform all study staff, including the pharmacy and support laboratories of the dates of the Regulatory Agency visit and the study to be reviewed. First impressions are important be available. Examine the credentials of the inspector, and establish the purpose of the inspection. Assume a cooperative attitude. Work out a rough schedule for the visit so that key personnel can be made available. Make sure you understand the questions before responding. Answer questions directly, do not volunteer information. Give honest, complete and accurate answers. Take complete notes as you go along. Take immediate corrective or remedial action, if appropriate. Call the sponsor is information is needed to support a response. When making copies for the inspector, make one extra set for you. Solicit opinions. Discuss your personal opinions about the study. Respond to questions outside your expertise. Volunteer information. Guess what the response to a question should be. Entertain hypothetical questions. Read, sign or listen to affidavits. Delay in providing requested records or copies.
6 Resources Food and Drug Administration. Compliance Program Guidance Manual. Available at: Published September 2, Accessed May 20, 2008 Marcarelli M, Device Clinical Trials Regulatory Considerations. SoCRA SOURCE. May 2003; Available at: Accessed May 20, Health Product and Food Branch Inspectorate. Summary report of the inspections of clinical trials conducted in 2003/2004. Available at: Published December 14, Accessed May 21, NHS Research and Development Forum. How to prepare for an inspection for Good Clinical Practice by the Medicines and Healthcare products Regulatory Agency (MHRA): a guide for NHS organizations that sponsor or host clinical trials of medicinal products. Available at: group.shef.ac.uk. Published November 6, Accessed May 21, Food and Drug Administration. Information sheet guidance for IRBs, clinical investigators, and sponsors. Available at: Published January Accessed May 21, European Medicines Agency. Joint Audit Programme for EEA GMP Inspectors. Available at: www. emea.europa.eu. Published September 19, Accessed May 20, Health Products and Food Branch Inspectorate. Health Canada website. Available at: Accessed May 20, Neckers K. Harmonization of drug and medical device development in the US and Japan: movement towards international cooperation in the postgenomic Era. New England International and Comparative Law Annual 2006;12:65-96.
How to Prepare for Federal Inspections and What to Expect
How to Prepare for Federal Inspections and What to Expect Jennifer A. Graf Tufts Medical Center Tufts University Health Sciences Director of IRB Operations Originally presented at the February 2011 Society
More informationWIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)
WIRBinar How to Survive an FDA Inspection 10-26-2011 Brought to you by WIRB Education and Consulting Services. Improve your ability to maintain compliance and protect human subjects with guidance from
More informationFDA Inspection Readiness
FDA Inspection Readiness Richard Angelo, Ph.D. Director, Managing Consultant October 17, 2014 Agenda Reasons for Inspections Preparing for Inspections Inspection Day Inspection Outcomes 2013 Inspection
More informationFDA Inspectional Process in Clinical Research An FDA Perspective. Annette Melendez, MPHsN Investigator Office of Biological Products Operations
FDA Inspectional Process in Clinical Research An FDA Perspective Annette Melendez, MPHsN Investigator Office of Biological Products Operations Outline BIMO PROGRAM OVERVIEW PROGRAM COVERED AREAS INSPECTIONAL
More informationRegulatory Inspections
Regulatory Inspections An Overview of Process, Observations, and Guidance for Investigators Alison Urton, Group Administrator Clive Hansen, Audit Team Leader Outline Regulatory History Health Canada Overview
More informationPostmarketing Drug Safety and Inspection Readiness
Postmarketing Drug Safety and Inspection Readiness June 19, 2018 Center for Drug Evaluation and Research (CDER) Small Business and Industry Assistance (SBIA) Webinar United States Food and Drug Administration
More informationThe GCP Perspective on Study Monitoring
The GCP Perspective on Study Monitoring Heidi Judge, CCRP Sr. Clinical Trials Project Manager Clinical Trials Network and Institute Massachusetts General Hospital 1 Overview Monitoring Basics Who, What,
More informationBIMO SITE AUDIT CHECKLIST
Item AUTHORITY AND ADMINISTRATION FOR STUDIES INVOLVING HUMAN DRUGS, BIOLOGICS AND DEVICES 1. Compare the Investigator Agreement with the information provided by the assigning Center. Auditor will check
More informationWARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Charles J. Coté, M.D. Ref: 09-HFD-45-02-04
More informationSTANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager
STANDARD OPERATING PROCEDURE SOP 710 Good Clinical Practice AUDIT AND INSPECTION Version 1.3 Version date 27.02.2018 Effective date 3.03.2018 Number of pages 10 Review date February 2020 Author Role Approved
More informationResearch Governance Framework 2 nd Edition, Medicine for Human Use (Clinical Trial) Regulations 2004
Title: Outcome Statement: Research Auditing and Monitoring Procedures Researchers in the Trust and research partners will be informed about the requirements and procedures involved in research audit and
More informationSuccessful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics
Vol. 9, No. 1, January 2013 Happy Trials to You Successful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics By Swati Tendolkar The United States Food and Drug Administration
More informationGuideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol
1 2 31 January 2017 EMA/430909/2016 3 4 5 Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or Draft Adopted by GCP Inspectors Working Group (GCP IWG) 30 January 2017 Adopted
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES WARNING LETTER. (b) (4) clinical investigation (Protocol entitled A Phase II, Multicenter,
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Ronald Bukowski, M.D. 28099 Gates Mills
More informationTrial Management: Trial Master Files and Investigator Site Files
Title: Outcome Statement: Written By: Trial Management: Trial Master Files and Investigator Site Files Staff working on research studies in NSFT will be informed about the requirements of setting up and
More informationInspections and Study Monitoring
Inspections and Study Monitoring IRB Education Series 2006 Presentation may only be reused or reprinted with written permission from the Tufts-New England Medical Center/Tufts University IRB office. Audits
More informationmanaging or activities.
STANDARD OPERATING PROCEDURE Clinical Research Monitoring TITLE: Site Initiation Visit TITLE: Site Initiation Visit 1. PURPOSE SOP Number: Version: 1.0 MICHR CRM MON 002 Effective Date: 19Dec2013 1.1 This
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More informationEssential Documents It s Not Just a Binder!
Essential Documents It s Not Just a Binder! Kelly Unsworth, MS, CCRC, CIP Director of Research Education & Training Office for Human Subject Protection SCORE June 5, 2014 But What percentage of 2014 (to
More informationInvestigator Roles and Responsibilities in Clinical Device Trials
Investigator Roles and Responsibilities in Clinical Device Trials A Total Product Lifecycle Approach to Medical Device Development: Responsibilities and Opportunities The Stanford Center for Clinical and
More informationQUALITY TIPS FOR CLINICAL SITES. Athena Thomas-Visel. Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES
QUALITY TIPS FOR CLINICAL SITES Athena Thomas-Visel Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES Purpose of presentation: Share best practices seen from 150+ sites visited Spark conversation
More informationGood Clinical Practice: A Ground Level View
Good Clinical Practice: A Ground Level View Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Clinical Research Administration Research Institute,
More informationVersion Number: 004 Controlled Document Sponsor: Controlled Document Lead:
Chief Investigators and Principal Investigators in Research Policy CONTROLLED DOCUMENT CATEGORY: CLASSIFICATION: PURPOSE Controlled Document Number: Policy Governance To set out the responsibilities of
More informationSPONSOR-INVESTIGATOR ROLES & RESPONSIBILITIES IN DEVICE TRIALS
SPONSOR-INVESTIGATOR ROLES & RESPONSIBILITIES IN DEVICE TRIALS Food and Drug Administration Center for Devices and Radiological Health Office of Compliance Division of Bioresearch Monitoring Doreen Kezer,
More informationTomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan
Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan The views presented in this presentation are those of the author and should not be understood or quoted as being made
More informationFDA Medical Device Regulations vs. ISO 14155
Vol. 11, No. 9, September 2015 Happy Trials to You FDA Medical Device Regulations vs. ISO 14155 By Shawn Kennedy Medical device clinical trials must comply with 21 CFR Parts 11 (Electronic Records), 50
More informationVCU Clinical Research Quality Assurance Assessment
VCU Clinical Research Quality Assurance Assessment Principal Investigator Protocol Title Protocol IRB Number Name of Person Completing Assessment Date Assessment was Completed The goal of this assessment
More informationStandard Operating Procedures
Clinical Monitoring and Site Verification Procedure Overview To define the standard procedures for preparation and documentation of site visits for clinical monitoring and spoke verification for any NETT
More informationAn Update on FDA s Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies Proposed Rule
An Update on FDA s Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies Proposed Rule SOT: Regulatory and Safety Evaluation Specialty Section Webinar September 29, 2017 Mark Seaton, Ph.D.,
More informationDocument Title: Document Number:
including Document Title: Document Number: Version: 2.0 Ratified by: Committee Date ratified: 25/01/2018 Name of originator/author: Directorate: Department: Name of responsible individual: Rachel Fay Corporate
More informationEMA Inspection Site perspective
EMA Inspection Site perspective Hermien Gous Wits RHI Shandukani Research Centre 27.09.2016 Cape Town Why were we inspected times? Pharmaceutical company applied for registration of the study drug in a
More informationResearch Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review
Effective: 12/04/2013 Reviewed: 12/04/2015 Name of Associated Policy: Palmetto Health Administrative Research Review Definitions Responsible Positions Equipment Needed Procedure Steps, Guidelines, Rules,
More informationDocument Title: Study Data SOP (CRFs and Source Data)
Document Title: Study Data SOP (CRFs and Source Data) Document Number: SOP047 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationDefinitions: In this chapter, unless the context or subject matter otherwise requires:
CHAPTER 61-02-01 Final Copy PHARMACY PERMITS Section 61-02-01-01 Permit Required 61-02-01-02 Application for Permit 61-02-01-03 Pharmaceutical Compounding Standards 61-02-01-04 Permit Not Transferable
More informationDocument Number: 006. Version: 1. Date ratified: Name of originator/author: Heidi Saunders, Senior Portfolio Coordinator
including Roles and Responsibilities for the Conduct of Research Studies and Clinical Trials including CTIMPs (Clinical Trials of Investigational Medicinal Products) Document Number: 006 Version: 1 Ratified
More informationMEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS Memorandum of understanding between MHRA, COREC and GTAC
MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 Memorandum of understanding between MHRA, COREC and GTAC 1. Purpose and scope 1.1 Regulation 27A of the Medicines for Human Use (Clinical Trials)
More informationRoles & Responsibilities of Investigator & IRB
Roles & Responsibilities of Investigator & IRB Jaranit Kaewkungwal Mahidol University Regulatory & Guidelines Regulatory & Guidelines GCP & Computer / Database Management Systems International Conference
More informationPROMPTLY REPORTABLE EVENTS
PROMPTLY REPORTABLE EVENTS PURPOSE AND SCOPE To define the structure and responsibility for reporting unanticipated problems that occurs during the conduct of research. APPLICABLE REGULATIONS Policy II.02
More informationRoles of Investigators in the Managements of Clinical Trials
Roles of Investigators in the Managements of Clinical Trials Chii-Min Hwu, M.D. Section of General Medicine Department of Medicine Taipei Veterans General Hospital Learning Objectives PI Outlines How to
More information4.2. Clinical Trial Monitor (or Monitor): The person responsible for monitoring the data on behalf of the sponsor or contract research organization.
SOP #: MON-101 Page: 1 of 6 1. POLICY STATEMENT: The DF/HCC understands that external sponsors are required to monitor the progress of clinical investigations and ensure appropriate research data collection
More informationOffice of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators
Office of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators Patricia Fischer, RN, CCRP Investigator Responsibilities FDA Draft Guidance May 2007 Clarifies FDA s expectations,
More informationBIMO Program Update an operational perspective
BIMO Program Update an operational perspective Clinical Trials Summit San Juan, Puerto Rico May 9, 2018 Anne E. Johnson Program Division Director FDA/ORA/OBIMO Division I (East) 1 Objectives Program Alignment
More informationLast updated on April 23, 2017 by Chris Krummey - Managing Attorney-Transactions
Physician Assistant Supervision Agreement Instructions Sheet Outlined in this document the instructions for completing the Physician Assistant Supervision Agreement and forming a supervision agreement
More information12.0 Investigator Responsibilities
12.0 Investigator Responsibilities 12.1 Policy Investigators are ultimately responsible for the conduct of research. Research must be conducted according to the signed Investigator statement, the investigational
More informationA Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky
A Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky I. Compliance with IRB and Applicable Federal Requirements A. Investigators
More informationAAHRPP Accreditation Procedures Approved April 22, Copyright AAHRPP. All rights reserved.
AAHRPP Accreditation Procedures Approved April 22, 2014 Copyright 2014-2002 AAHRPP. All rights reserved. TABLE OF CONTENTS The AAHRPP Accreditation Program... 3 Reaccreditation Procedures... 4 Accreditable
More informationGCP Inspection by PMDA
2012 EU GCP Inspectors Working Group Workshop London, 12-14 November 2012 Practical Experience in GCP inspections, non EU/EEA countries GCP Inspection by PMDA Kazuko Natsui Inspector for GCP Inspection,
More information1. Department of Defense (DoD) Human Subjects Protection Regulatory Requirements
Information for Investigators: Headquarters, U.S. Special Operations Command Human Research Protection Office (HRPO) Human Research Protections Regulatory Requirements 1. Department of Defense (DoD) Human
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Dallas Jr, Anthony V, MD 11/09/09 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring,
More informationSOP-QA-28 V2. Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head of School
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Richard Cowie, QA Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head
More informationInitially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009 1:51 PM Approval By student13 student13 on 11/24/2009 1:52 PM Attendees
Location: Los Angeles Research Institute: Los Angeles, CA Investigation Product/Test Article: Laftr Visit Mechanism: On-site Initially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009
More informationGAO MEDICAL DEVICES. Status of FDA s Program for Inspections by Accredited Organizations. Report to Congressional Committees
GAO United States Government Accountability Office Report to Congressional Committees January 2007 MEDICAL DEVICES Status of FDA s Program for Inspections by Accredited Organizations GAO-07-157 Accountability
More informationAbout the PEI College of Pharmacists
CODE OF ETHICS About the PEI College of Pharmacists The PEI College of Pharmacists is the registering and regulatory body for the profession of pharmacy in Prince Edward Island. The mandate of the PEI
More informationDocument Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026
Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026 Version: 1.1 Ratified by: Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department:
More informationHIC Standard Operating Procedure. For-Cause Audits of Human Research Studies
HIC Standard Operating Procedure For-Cause Audits of Human Research Studies Background As part of the Wayne State University (WSU) Human Investigation Committee s (HIC) Human Research Protection Program,
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Routine Project Audit SOP Number: 6 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date: August
More informationStandard Operating Procedure Research Governance
Research and Enterprise Standard Operating Procedure Research Governance Title: Research Governance Audit SOP Reference Number: QUB-ADRE-08 Date prepared 7 August 008 Version Number: Final v -6.0 Revision
More informationACTIONS/PSOP/001 Version 1.0 Page 2 of 6
1. The purpose of the Pharmacy Site File To enable the designated trust pharmacy to fulfil its role and exercise appropriate control over all aspects of study medication handling, an accurately maintained
More informationHigh level guidance to support a shared view of quality in general practice
Regulation of General Practice Programme Board High level guidance to support a shared view of quality in general practice March 2018 Publications Gateway Reference: 07811 This document was produced with
More informationDr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015
18 August 2015 Role & Responsibilities of Principal Dr. R. Sathianathan Professor of Psychiatry, SRMC, Porur & Former Director, Institute of Mental Health, Chennai Principal Investigators & GOOD CLINICAL
More informationPreparing for and responding to an FDA Inspection Frank Estala Kathy James Clara Vorpahl Anna Taranova
Preparing for and responding to an FDA Inspection Frank Estala Kathy James Clara Vorpahl Anna Taranova Disclosures The speakers have no relevant financial and non-financial relationships to disclose. The
More informationMARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: MCCCRO-D
Page 1 of 8 MARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: Title: Data Safety and Monitoring Committee Administrative and Revision: N/A Revision Date: N/A Functional
More informationSARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY
PS1006 SARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY TITLE: Satellite Site Management Plan Job Title of Reviewer: POLICY #: EFFECTIVE DATE: REVISED DATE: POLICY TYPE: Elizabeth Carr, R.N.,
More informationFDA s Clinical Trial Inspections in China Including FDA Overall Goals
FDA s Clinical Trial Inspections in China Including FDA Overall Goals Prepared for You by Barbara Kephart Immel, President, Immel Resources LLC 2013, Immel Resources LLC 1 Overview Budget China Initiative
More informationNOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE) LETTER
DEPARTMENT OF HFM3-H & HWMAN SERVICES Public Health Service SEP 3 0 20()4 Food and Drug Admmistration Center for Devices and Radiological Health 2098 Gaither Road Rockville, MD 20850 NOTICE OF INITIATION
More informationMonitoring Clinical Trials
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationAssessment Framework for Designated Centres for Persons (Children and Adults) with Disabilities
Assessment Framework for Designated Centres for Persons (Children and Adults) with Disabilities January, 2015 1 About the The (HIQA) is the independent Authority established to drive high quality and safe
More informationTrial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs
R&D Department Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More informationFINAL DOCUMENT. Global Harmonization Task Force
GHTF/SG5/N5:2012 FINAL DOCUMENT Global Harmonization Task Force Title: Reportable Events During Pre-Market Clinical Investigations Authoring Group: Study Group 5 of the Global Harmonization Task Force
More informationStudy Management SM STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting
Study Management SM 306.00 STANDARD OPERATING PROCEDURE FOR Adverse Event Reporting Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick M. Schnell, MD,
More informationWARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED. Ref: 06-HFD
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Evangeline G. Gonzalez, M.D. Gonzalez
More information11/18/2016. UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities SESSION 4
UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities BEVERLY ALGER, CCRP, CHRC Research Compliance Officer Office of Research Compliance November 2016
More informationWelcome to LifeWorks NW.
Welcome to LifeWorks NW. Everyone needs help at times, and we are glad to be here to provide support for you. We would like your time with us to be the best possible. Asking for help with an addiction
More informationEMA & FDA Inspections: Site perspective. Shandukani Research Centre
EMA & FDA Inspections: Site perspective Shandukani Research Centre Why were we inspected? Pharmaceutical company applied for registration of the study drug (Phase I/II dosing studies in paediatrics) Large
More informationClinical Trials at PMH
Clinical Trials at PMH What You Need To Know UHN Patient Education Improving Health Through Education A Guide for Patients, Their Families and Friends in the PMH Cancer Program This information is to be
More informationSTUDY INFORMATION POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812)
POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812) Purpose: Investigators who initiate and submit an IDE application to the FDA assume the responsibilities of both
More informationTITLE: Reporting Adverse Events SOP #: RCO-204 Page: 1 of 5 Effective Date: 01/31/18
SOP #: RCO-204 Page: 1 of 5 1. POLICY STATEMENT: The research team is responsible for recognizing changes in subject health that may qualify as adverse events, classifying those results as defined in the
More informationTraining components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA
Training components for GCP inspectors in PMDA Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA Content 1. Conformity inspection in the training program for newcomers to PMDA 2. The training
More informationRESEARCH SUPPORTED BY A DEPARTMENT OF DEFENSE (DOD) COMPONENT
DUKE UNIVERSITY HEALTH SYSTEM Human Research Protection Program RESEARCH SUPPORTED BY A DEPARTMENT OF DEFENSE (DOD) COMPONENT 5/23/2011 The following special considerations apply to research involving
More informationISDN. Over the past few years, the Office of the Inspector General. Assisting Network Members Develop and Implement Corporate Compliance Programs
Information Bulletin #7 ISDN National Association of Community Health Centers, Inc. INTEGRATED SERVICES DELIVERY NETWORKS SERIES For more information contact Jacqueline C. Leifer, Esq. or Marcie H. Zakheim,
More informationI. Preamble: II. Parties:
I. Preamble: MEMORANDUM OF UNDERSTANDING BETWEEN THE FEDERAL COMMUNICATIONS COMMISSION AND THE FOOD AND DRUG ADMINISTRATION CENTER FOR DEVICES AND RADIOLOGICAL HEALTH The Food and Drug Administration (FDA)
More informationChecklist prior to recruiting first patient
Pre-Site selection Site Initiation Visit (SIV) What kind of questions should you ask How you should prepare for this visit Delegation logs Training logs ECRF/CRF Checklist prior to recruiting first patient
More informationNOVA SOUTHEASTERN UNIVERSITY
NOVA SOUTHEASTERN UNIVERSITY DIVISION OF RESPONSIBILITIES FOR RESEARCH AND SPONSORED PROGRAMS Vice President of Research & Technology Transfer: The responsibilities of the Vice President of Research &
More informationPage 2- Alan Rapoport, M.D.
~ I^ 1 ) ~~ ~~ ls sr~ L DEPA RTMENT OF HEALTH & HUMAN SERViCES Public Health Se rvice J~T~ ;awyicf,{,~-
More informationClinical Research Professionals
Training & Resources for Clinical Research Professionals Course & Publications Catalog January July 2016 In-Person and Web-Based Training Courses, Customized Training, elearning and Publications for Clinical
More informationEffective Date: April 2014 Revision: September 29, Executive Chair, Co-Chairs, NSHA REB Members, REB Office Personnel, Researchers.
TITLE: Standard Operating Procedure (SOP) External Inspections or Audits NUMBER: NSHA REB-SOP-9-002 Effective Date: April 2014 Revision: September 29, 2017 Applies To: Executive Chair, Co-Chairs, NSHA
More informationPROFESSIONAL STANDARDS FOR MIDWIVES
Appendix A: Professional Standards for Midwives OVERVIEW The Professional Standards for Midwives (Professional Standards ) describes what is expected of all midwives registered with the ( College ). The
More informationPablo Tebas, M.D. Joseph Quinn, RN, BSN Yan Jiang, RN, BSN, MSN
Gilead Sciences, Inc. / Protocol Number GS-US-380-1489 Page 1 of 9 PARTNER PREGNANCY FOLLOW UP CONSENT FORM Sponsor / Study Title: Protocol Number: Principal Investigator: (Study Doctor) Gilead Sciences,
More informationMHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager
MHRA Findings Dissemination Joint Office Launch Jan. 2012 Presented by: Carolyn Maloney UHL R&D Manager Purpose of presentation To feed back abridged findings from March 2011 MHRA Statutory Systems Inspection
More informationSolutions for GCP Compliance Challenges. September 23, 2015 Northwestern University IRB Brown Bag Session
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
More informationSolutions for GCP Compliance Challenges
Solutions for GCP Compliance Challenges September 23, 2015 Northwestern University IRB Brown Bag Session PAMELA MASON, MPH Vice President, Mason Professional Services, LLC Adjunct Faculty, Northwestern
More informationGuidance for the assessment of centres for persons with disabilities
Guidance for the assessment of centres for persons with disabilities September 2017 Page 1 of 145 About the Health Information and Quality Authority The Health Information and Quality Authority (HIQA)
More informationOverview of the IMB s. Good Clinical Practice. Deirdre O Regan GCP/Pharmacovigilance. GCP Seminar Dublin, 27 th January 2010.
Overview of the IMB s Approach to Inspection of Good Clinical Practice GCP Seminar Dublin, 27 th January 2010 Deirdre O Regan GCP/Pharmacovigilance Inspection Manager Slide 1 Introductions/Organisation
More informationColorado Board of Pharmacy Rules pertaining to Collaborative Practice Agreements
6.00.00 PHARMACEUTICAL CARE, DRUG THERAPY MANAGEMENT AND PRACTICE BY PROTOCOL. 6.00.10 Definitions. a. "Pharmaceutical care" means the provision of drug therapy and other pharmaceutical patient care services
More informationSafety Reporting in Clinical Research Policy Final Version 4.0
Safety Reporting in Clinical Research Policy Final Version 4.0 Category: Summary: Equality Assessment undertaken: Impact Policy The Medicines for Human Use (Clinical Trials) Regulations 2004 and subsequent
More informationNHS and independent ambulance services
How CQC regulates: NHS and independent ambulance services Provider handbook March 2015 The Care Quality Commission is the independent regulator of health and adult social care in England. Our purpose We
More informationTHE CODE. Professional standards of conduct, ethics and performance for pharmacists in Northern Ireland. Effective from 1 March 2016
THE CODE Professional standards of conduct, ethics and performance for pharmacists in Northern Ireland Effective from 1 March 2016 PRINCIPLE 1: ALWAYS PUT THE PATIENT FIRST PRINCIPLE 2: PROVIDE A SAFE
More informationCOMPLIANCE PLAN PRACTICE NAME
COMPLIANCE PLAN PRACTICE NAME Table of Contents Article 1: Introduction A. Commitment to Compliance B. Overall Coordination C. Goal and Scope D. Purpose Article 2: Compliance Activities Overall Coordination
More informationStudy Monitoring Plan Template
Study Monitoring Plan Template Sponsor Reference Number: Study Title: Principal Investigator: Study Centre: The Sponsor risk assessment form and the trial risk based monitoring strategy appendices 2 &
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service 3%3&4 JUL 1 3 2CG3 WARNING LETTER Food and Drug Administration Center for Devices and Radiological Health 2098 Gaither Road Rockville, MD 20850
More information